The public message board needs "Badge 714", just the facts..It is amusing to watch the oh so meaningful back and forth banter, delightful really. Keep doing it so I am compelled to share more fun facts that seem to best "ignored" ; - )
I still wonder how it is people don't really understand the benefits of having an ultra-low ajustable cost basis....just because some have been able to "benefit" does NOT at all make it right.
How can a CFO, with all the "credentials" and a wonderfully seasoned board of directors on duty, decide to split $6.6 MILLION CAD "no strings attached" revenue dollars from Baxter Medical ( a major pharma ) into 108 tiny pieces over 9 years or "108 months" and then pull the real rabbit out of the hat by applying a curious and less than transparent one-time "legacy charge" of $1.7M CAD that turns the Spectral's BIGGEST to-date single win into a perfect losing canvas to finance at 60 cents CAD, followed by 42.5 cents CAD to the CFO's former employer? In my opinion this, together with the ill-advised "Eve O' Pandemic" finanacing... decided against, but costing us 175K CAD for his/our trouble, started the cascade of errors that led to the printing of about 50 MILLION additional shares at and average cost in the 50 cent CAD area. Bear in mind, phase 2 BELLUS ( T.BLU ) just raised $200M USD with shares priced at ~$8 USD on the back of phase 2 topline "chronic cough" data. This was "SOLD" to the public, NOT taken down buy the CFO's former employer.
It is interesting, just as it was to have the 20 year custodian of the bullboard use the "nail in the coffin" line to describe our "voluntary" decision to BLOCK each and every news release on FDA advancement from reaching the US market over the past 61 MONTHS. This includes PMX, SAMI, DIMI and of course the hiring of perhaps our (America's) greatest key opinion leader in EXACTLY our ( Spectral's ) area of expertise...
Sumthin's NOT right is Mr. Mercedes? ; - )
Nasty isn't it? ..the below post brought to you minutes after it was released. "Viking-fellow" often provides the bullboard with news just minutes after it's release. Remember Davi-king claims to be from Edmonten ( 2 or 3 hours behind us here in the east ), he does get up early to treat those ready to absorb the "stories" .....as they say bon appetito!
daviking (158)
User Actions
December 14, 2016 - 08:19 AM
193 Reads
Post# 25596846
Is this another nail in the coffin? What is everyone's take?
Spectral Medical Inc.December 14, 2016 08:00 ET
Spectral Voluntarily Delists From OTCQX
TORONTO, ONTARIO--(Marketwired - Dec. 14, 2016) -Spectral Medical Inc. ("Spectral" or the "Company") (TSX:EDT)(OTCQX:EDTXF), a Phase III company developing the first treatment for patients with endotoxemic septic shock using a medical device, today announced that after a detailed review of the trading volume, costs and administrative requirements related to maintaining the Company's listing on the OTCQX, it has voluntarily delisted its Common shares from the OTCQX effective January 1, 2017. Spectral's Common shares will continue to be listed on the Toronto Stock Exchange.
About Spectral Medical Inc.
Spectral is a Phase III company seeking U.S. FDA approval for its unique product Toraymyxin™ ("PMX") for the treatment of patients with septic shock. PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is directed by the Company's Endotoxin Activity Assay (EAA™), the only FDA cleared diagnostic for the risk of developing sepsis.
PMX has been approved for therapeutic use in Japan and Europe, and has been used safely and effectively on more than 150,000 patients to date. Approximately 350,000 patients are diagnosed with severe sepsis and septic shock in North America each year. Currently there is no specific treatment available for this condition.
Spectral is listed on the Toronto Stock Exchange under the symbol EDT. For more information please visit www.spectraldx.com.
Forward-looking Statement
Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of Spectral and anticipated events or results, are assumptions based on beliefs of Spectral's senior management as well as information currently available to it. While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Spectral to commercialize its products, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities as well as general economic, market and business conditions, and could differ materially from what is currently expected.
The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement.
Contact Information
Anthony Businskas
Executive Vice President and CFO
Spectral Medical Inc